For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Revenue | 0 | |||
| Research and development | 34,068,000 | |||
| General and administrative | 18,351,000 | |||
| Restructuring | -172,000 | |||
| Total operating expenses | 52,247,000 | |||
| Loss from operations | -52,247,000 | |||
| Interest expense | 473,000 | |||
| Interest and other income, net | 709,000 | |||
| Accretion of discount on investments, net | 1,679,000 | |||
| Net loss | -50,332,000 | |||
| Earnings per share, basic, total | -0.45 | |||
| Earnings per share, diluted, total | -0.45 | |||
| Weighted average number of shares outstanding, basic, total | 111,571,136 | |||
| Weighted average number of shares outstanding, diluted, total | 111,571,136 | |||
ROCKET PHARMACEUTICALS, INC. (RCKTW)
ROCKET PHARMACEUTICALS, INC. (RCKTW)